Ro and Novo will present additional first-of-its-kind research during ObesityWeek 2026 (November 14-17, 2026), including ...
In the Phase 3 open-label extension clinical trial (OLE), patients with moderate to severe acne received denifanstat for up ...
Astrocyte Pharmaceuticals Inc., a pioneering clinical-stage biotechnology company developing first-in-class cerebroprotective ...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in ...
Summit Therapeutics scores a $2 billion equity investment from AstraZeneca to support ivonescimab’s late-stage development; ...
Newronika S.p.A., a medical technology company developing adaptive deep brain stimulation therapies, today announced that the ...
Label, Single-Arm SYNCHRONICITY Trial will be presented in a late-breaking oral presentation during Uveitis Subspecialty Day ...
Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting ...
People with overweight or obesity who switched from injectable GLP-1 based therapies for weight management to oral ...
(NASDAQ:MRNA) today announced the addition of a Chief Operating Officer role to support the increasing scale and ...
New data suggest that givinostat treatment may slow the decline of upper limb function in boys with Duchenne muscular ...
HMBD-001, a differentiated anti-HER3 monoclonal antibody discovered and developed with Hummingbird Bioscience’s AI Molecular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results